ACM
ICPT

Atika Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Atika Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,200
Closed -$521K – 78
2014
Q2 		$521K Sell
2,200
-11,380
-84% -$3M 0.42% 55
2014
Q1 		$4.48M Sell
13,580
-5,420
-29% -$1.83M 3.81% 6
2013
Q4 		$1.3M Buy
+19,000
New +$1.1M 1.15% 36

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's ICPT Position: Q3 2014 in Review

Atika Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2014, closing a stake of 2,200 shares — an estimated $521K sold.

Atika Capital Management first reported a position in ICPT in Q4 2013 and held it in 3 quarters. The position peaked at $4.48M in Q1 2014. 181 funds tracked by Wall St. Rank hold ICPT as of Q3 2014.

  • Atika Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Atika Capital Management sold 2,200 Intercept Pharmaceuticals, Inc. shares in Q3 2014, an estimated $521K.
  • Atika Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 3 quarters.
  • Atika Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $4.48M in Q1 2014.
  • 181 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2014.

Based on Atika Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.